Silo Pharma receives Canadian patent allowance for SPC-15 drug

Silo Pharma has received a patent allowance from Canada for their drug SPC-15, a nasal treatment aimed at treating stress-related psychiatric disorders. The patent application, titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress," covers methods of preventing or delaying stress-induced fear and depressive-like behavior using serotonin 4 receptor agonists.

Silo Pharma has an exclusive license for the Canadian patent as part of a broader agreement with Columbia University to develop, manufacture, and sell SPC-15 worldwide. The company has also secured intellectual property rights in various international markets, including a recent European patent for the same invention. Silo Pharma is currently using the FDA's 505(b)(2) regulatory pathway for SPC-15 development and is a biopharmaceutical company focused on treatments for stress-induced psychiatric disorders, chronic pain, and central nervous system diseases.